Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Purchases of Investments
Cash used to buy marketable securities and other investments.
Tenax Therapeutics, Inc.NASDAQ: TENX
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments outflow grows to $0
Q1 FY2026 purchases of investments was $0, compared with $0 a year earlier. Trailing-twelve-month purchases of investments was $0.
Context
- Purchases of investments increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly purchases of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (345.54K) | — |
Purchases of Investments vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's LTM Mar 2026 purchases of investments of $0 is the 5th largest of the 7 companies compared; the peer median is $89.13M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $55.13B | — | — | — | |
| LTM Jun 2026 | $433.45M | +6853.0% | — | — | |
| LTM Mar 2026 | $151.68M | -36.8% | +60.1% | — | |
| LTM Mar 2026 | $26.59M | -61.5% | -21.0% | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TENX) | $89.13M | -36.8% | +19.5% | 0.0% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.47M) | (11.05M) | (7.71M) | (17.6M) | (52.6M) |
| Depreciation & Amortization | 108.98K | 113.33K | 8K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 191K | 1.13M | 0 |
| Change in Working Capital | (610.09K) | (1.45M) | 1.58M | 1.64M | (2.36M) |
| Accounts Receivables | (22.5K) | 0 | (306K) | 58K | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | (344.95K) | 1.65M | 1.06M | 2.88M |
| Other Working Capital | (587.59K) | (1.1M) | 237K | 523K | (5.25M) |
| Other Non-Cash Items | 22.12M | 366.86K | 25K | 23K | 19.16M |
| Operating Cash Flow | (10.86M) | (12.01M) | (5.9M) | (14.81M) | (35.8M) |
| Capital Expenditures | (5.25K) | (2.33K) | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (345.54K) | 0 | 0 | 0 | 0 |
| Sales of Investments | 803.4K | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 3K | 0 | 0 |
| Investing Cash Flow | 452.61K | (2.32K) | 3K | 0 | 0 |
| Debt Repayment | 0 | 624.3K | (624K) | (501K) | 0 |
| Common Stock Issued | 9.19M | 7.93M | 14.19M | 100.37M | 38.51M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 544.65K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 9.74M | 8.55M | 13.57M | 99.87M | 38.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (666.32K) | (3.46M) | 7.67M | 85.06M | 2.71M |
| Free Cash Flow | (10.86M) | (12.02M) | (5.9M) | (14.81M) | (35.8M) |
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.